Are Price Controls Killing Innovation? | RealClearHealth Podcast 101

On the first episode of the new RealClearHealth podcast, we discuss the challenges facing American healthcare with the people shaping the debate. Is there common ground in a polarized political landscape? What are the tensions between competition and price controls? How can America promote transparency over complexity, patients over middlemen, and innovation together with affordability?

Host and RealClearHealth Editor, Jerry Rogers is joined by Andrew Langer, a prominent American public policy advocate, media personality, and expert on regulatory and small-business issues. He is also the founder of the Main Street Foundation.

And by Eric Hargan, founder and CEO of The Hargan Group and a former Deputy Secretary of the U.S. Department of Health and Human Services, where he helped oversee the department’s operations and policy development.

And later in the show we’ll be joined by Gary Andres, Assistant Secretary for Legislation at HHS, who brings decades of experience in health policy, Congress, and the federal legislative process to the conversation about the future of American health care.

ADDITIONAL READING FOR THS EPISODE:

Congress Must End Washington’s Penalty on Prescription Pills | RealClearHealth

The HHS 340B Pilot: Steering the Program to Its Original Purpose | RealClearHealth

How Price Controls Could Drive Up Long-Term Drug Spending | RealClearHealth

Congress Must Act to Protect Patient Access to Cancer Care | RealClearHealth

America's Small Businesses Can't Afford 340B Abuse | RealClearHealth

Germany’s Pharmaceutical Free Ride May Finally Be Coming to an End | RealClearHealth

Europe's Drug Price Controls Are Undercutting American Leadership | RealClearHealth